64 active not recruiting. 64 Phase 1, 26 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 64 | Active not recruiting 64 |
| Phase 2 | 26 | Active not recruiting 26 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat NNC4005-001, Placebo - Fatty Liver Disease | Phase 1 | Active not recruiting | Novo Nordisk A/S | 29 | 2025-10-08 | 2026-10-13 |
| A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease Bepirovirsen - Hepatitis B | Phase 1 | Active not recruiting | GlaxoSmithKline | 32 | 2025-09-26 | 2026-05-22 |
| A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults SN2001 - Chronic Hepatitis B Infection | Phase 1 | Active not recruiting | Chimivac INC | 36 | 2025-08-19 | 2026-10-13 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors SH006 - Liver Cancer | Phase 1 | Active not recruiting | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 50 | 2025-07-01 | 2026-01-23 |
| Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation Intravenous esketamine using Dixon's up-and-down sequential method, Intravenous the dose of esketamine ED95, Intravenous fentanyl 1 μg∙kg-1 - Hepatic Neoplasm, Hepatic Cancer | Phase 1 / Phase 2 | Active not recruiting | The First Affiliated Hospital of Xiamen University | 79 | 2025-06-29 | 2025-09-11 |
| Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（4 hours）, Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（6 hours）, Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（8 hours） - Acute-On-Chronic Liver Failure | Phase 1 | Active not recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 15 | 2025-05-07 | 2025-05-30 |
| A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis | Phase 1 / Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 118 | 2025-04-28 | 2026-11-04 |
| A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma GKL-006 Injection, Transarterial chemoembolization (TACE) - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer | Phase 1 | Active not recruiting | Beijing Gene Key Life Technology Co., Ltd | 6 | 2025-04-03 | 2026-07-20 |
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer Cobolimab, Dostarlimab - Melanoma, Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 83 | 2025-03-06 | 2025-11-12 |
| Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants BMN 349, Placebo - Alpha 1-Antitrypsin Deficiency | Phase 1 | Active not recruiting | BioMarin Pharmaceutical | 6 | 2025-02-21 | 2026-05-06 |
| Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab SD-101, Cryotherapy, Tremelimumab - Hepatocellular Carcinoma | Phase 1 | Active not recruiting | University of California, San Diego | 16 | 2025-01-03 | 2026-07-28 |
| A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection HT-101, HT-102 - Chronic Hepatitis B | Phase 1 / Phase 2 | Active not recruiting | Suzhou HepaThera Biotech Co., Ltd. | 86 | 2024-12-30 | 2026-10-29 |
| RTX001 Autologous Engineered Macrophages for Liver Cirrhosis RTX001 - End-stage Liver Disease (ESLD), Cirrhosis, Liver | Phase 1 / Phase 2 | Active not recruiting | Resolution Therapeutics Limited | 30 | 2024-10-15 | 2026-10-05 |
| A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) Armored and GPC3-targeted autologous CAR T-cell - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Shanghai AbelZeta Ltd. | 121 | 2024-09-30 | 2026-10-13 |
| HepB mAb19 in Individuals With Chronic Hepatitis B Infection HepB mAb19, Sterile Saline - Hepatitis b Virus, Hepatitis B | Phase 1 | Active not recruiting | Rockefeller University | 37 | 2024-04-25 | 2026-10-13 |
| Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM). Dapagliflozin (DAPA), Placebo, Negative control - Diabetes Mellitus, Non Alcholic Fatty Liver Disease | Phase 1 / Phase 2 | Active not recruiting | Amira Bisher,PhD | 60 | 2024-01-15 | 2025-06-13 |
| A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma AZD5851 - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 94 | 2023-12-14 | 2026-08-19 |
| A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis b | Phase 1 / Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 88 | 2023-12-07 | 2024-11-14 |
| BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors BI-1910, Pembrolizumab - Solid Tumors, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | BioInvent International AB | 35 | 2023-12-04 | 2025-09-19 |
Showing 20 of 64. Sign in to see all of them.
Carcinoma, Hepatocellular (37) · Liver Neoplasms (15) · Carcinoma, Non-Small-Cell Lung (8) · Melanoma (8) · Colorectal Neoplasms (7) · Esophageal Neoplasms (7) · Neoplasms (7) · Ovarian Neoplasms (7) · Triple Negative Breast Neoplasms (7) · Carcinoma, Transitional Cell (6) · Lung Neoplasms (6) · Stomach Neoplasms (6) · Urinary Bladder Neoplasms (6) · Carcinoma, Renal Cell (5) · Endometrial Neoplasms (5)
Digestive System Diseases (64) · Neoplasms by Site (46) · Digestive System Neoplasms (45) · Neoplasms by Histologic Type (41) · Carcinoma (39) · Neoplasms (39) · Neoplasms, Glandular and Epithelial (39) · Adenocarcinoma (38) · Liver Neoplasms (30) · Pathological Conditions, Signs and Symptoms (18) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Urogenital Diseases (16) · Endocrine System Diseases (15)
durvalumab (6) · Magnetic Resonance Spectroscopy (4) · Nivolumab (4) · pembrolizumab (4) · Cyclophosphamide (3) · E-7386 (3) · Fluorodeoxyglucose F18 (3) · tremelimumab (3) · FAPI-46 (2) · Paclitaxel (2) · atezolizumab (2) · cabozantinib (2) · fludarabine (2) · lenvatinib (2) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1)
M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · Baylor College of Medicine (3) · City of Hope Medical Center (3) · AstraZeneca (2) · Eisai Inc. (2) · GlaxoSmithKline (2) · Jonsson Comprehensive Cancer Center (2) · AbbVie (1) · Amira Bisher,PhD (1) · Ascentawits Pharmaceuticals, Ltd (1) · Beijing Gene Key Life Technology Co., Ltd (1) · BioInvent International AB (1) · BioMarin Pharmaceutical (1) · Cancer Research UK (1)
United States (38) · Spain (11) · United Kingdom (11) · China (10) · France (7) · Canada (6) · South Korea (6) · Germany (5) · Italy (5) · Japan (5) · Australia (4) · Belgium (4) · Denmark (4) · Israel (2) · Netherlands (2)
Daneng Li (2) · Jeremie Calais (2) · Adam Burgoyne, MD, PhD (1) · Andres McAllister, PhD (1) · Anthony El-Khoueiry, MD (1) · Armeen Mahvash (1) · Caroline Labib, PharmD (1) · Chongyuan Xu, MD, PhD (1) · Dave Sprengers, MD, PhD (1) · David Steffin, M.D. (1)
PMID 34272087, PMID 34491815, PMID 35507536, PMID 35690072, PMID 38204489, PMID 39534099, PMID 39965176, PMID 40318924, PMID 40986544, PMID 42243349, PMID 42830785, PMID 42847673
2023 (3), P30CA033572 (2), 2016 (1), N01CM00100 (1), N01CN00042 (1), P30CA014089 (1), P30CA015083 (1), P30CA016672 (1), P30CA047904 (1), R01AA029398 (1), U01CA062490 (1), U01CA062502 (1), U01CA062505 (1), U01CA069856 (1), U01CA070095 (1)